Microba Life Sciences lists on ASX
Gut health business Microba Life Sciences (ASX: MAP) has successfully listed on the Australian Securities Exchange, in an initial public offering that raised $30 million.
Firm: Thomson Geer (Microba Life Sciences)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Microba has listed on the ASX following a $30 million IPO and was advised by Thomson Geer on all aspects of the listing, including legal requirements in relation to the prospectus and the due diligence process.
The IPO was backed by New York Stock Exchange-listed synthetic biology company Ginkgo Bioworks, which is backed by Bill Gates.
Area: Corporate, M&A
Value: $30 million
Key players: The Thomson Geer team was led by partner Emma Cook, who was supported by Belinda Pinnow and Robin Mahly.
Deal significance: Ms Cook said: “We were pleased to have been able to help Microba list on the ASX and enable investors to support its work in human health.”
The Lawyers Weekly Jobs Board has had a refresh! To check out the latest opportunities in private practice, in-house and more, click here.